SKION

Tisagenlecleucel (Kymriah®) as standard of care                  Tisagenlecleucel

Males ≤17 years of age undergoing allogeneic                       ALD-103
hematopoietic stem cell transplantation for the 
treatment of cerebral adrenoleukodystrophy                  

Patients 12-65 years of age with a diagnosis of                      NiCord III       
hematological malignancy who are candidates 
for unrelated cord blood transplantation, with 
qualifying HLA-matched UCB units with sufficient 
pre-cryopreserved total nucleated cell dose and 
CD34+ cell dose (see protocol for further specs)

Adult and adolescent patients ≥12 years old who                    REACH-2
have undergone allogeneic stem cell transplantation
and have developed Grade II-IV steroid refractory
acute graft vs. host disease.

Adult and adolescent patients ≥12 years old who                   REACH-3
have undergone allogeneic stem cell transplantation
and have developed moderate or severe steroid
refractory chronic graft versus host disease.

Pediatric patients (0-18 years old) receiving a                       PARACHUTE
non-T-cell depleted allogeneic hematopoietic                        (gesloten voor inclusie)
cell transplantation with Thymoglobulin in the
conditioning regimen as standard of care.